229 related articles for article (PubMed ID: 22639170)
1. Antigen-receptor gene-modified T cells for treatment of glioma.
Ikeda H; Shiku H
Adv Exp Med Biol; 2012; 746():202-15. PubMed ID: 22639170
[TBL] [Abstract][Full Text] [Related]
2. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
4. Cytokine therapy.
Ohno M; Natsume A; Wakabayashi T
Adv Exp Med Biol; 2012; 746():86-94. PubMed ID: 22639161
[TBL] [Abstract][Full Text] [Related]
5. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
[TBL] [Abstract][Full Text] [Related]
6. Genetically Modified Cellular Therapies for Malignant Gliomas.
Kilian M; Bunse T; Wick W; Platten M; Bunse L
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884607
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccines.
Yamanaka R; Kajiwara K
Adv Exp Med Biol; 2012; 746():187-200. PubMed ID: 22639169
[TBL] [Abstract][Full Text] [Related]
8. Basic concepts in glioma immunology.
Parney IF
Adv Exp Med Biol; 2012; 746():42-52. PubMed ID: 22639158
[TBL] [Abstract][Full Text] [Related]
9. T-cell immunotherapy for malignant glioma: toward a combined approach.
Dietrich PY; Dutoit V; Tran Thang NN; Walker PR
Curr Opin Oncol; 2010 Nov; 22(6):604-10. PubMed ID: 20739889
[TBL] [Abstract][Full Text] [Related]
10. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
11. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Eshhar Z
Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
[TBL] [Abstract][Full Text] [Related]
12. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
[TBL] [Abstract][Full Text] [Related]
14. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy for malignant glioma.
Mitchell DA; Fecci PE; Sampson JH
Cancer J; 2003; 9(3):157-66. PubMed ID: 12952301
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for glioma: from illusion to realistic prospects?
Dietrich PY; Dutoit V; Walker PR
Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
[TBL] [Abstract][Full Text] [Related]
18. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy of CNS malignancies.
Plautz GE; Shu S
Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
[TBL] [Abstract][Full Text] [Related]
20. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]